Bradycardia and Tachycardia Management - NREMT Paramedic Level

SECTION 1

Historical Context & Motivation

The ability to recognize and treat abnormal heart rates has been a defining challenge in emergency medicine for over a century. Before the advent of cardiac monitoring, clinicians relied solely on pulse palpation and auscultation to identify bradycardia (abnormally slow heart rate) and tachycardia (abnormally fast heart rate), two conditions that can rapidly deteriorate into cardiac arrest if left untreated. The evolution from crude pharmacological interventions to today's evidence-based ACLS algorithms represents decades of clinical research, technological breakthroughs, and iterative guideline development by organizations such as the American Heart Association.

1903 • Einthoven's Electrocardiograph

Willem Einthoven develops the string galvanometer, creating the first practical electrocardiogram (ECG). For the first time, clinicians could visualize cardiac electrical activity and distinguish between rhythm disturbances objectively.

1952 • First External Pacemaker

Paul Zoll demonstrates that external electrical stimulation can restore an adequate heart rate in patients with symptomatic bradycardia, establishing transcutaneous pacing as a life-saving intervention.

1962 • Direct-Current Cardioversion

Bernard Lown introduces synchronized direct-current cardioversion, enabling clinicians to safely terminate tachyarrhythmias by delivering a precisely timed electrical shock during the cardiac cycle.

1974 • First AHA ACLS Guidelines

The American Heart Association publishes its inaugural Advanced Cardiovascular Life Support (ACLS) standards, creating systematic algorithms for dysrhythmia management that would become the global standard of care.

2020 • AHA Guideline Update

The most recent AHA update refines bradycardia and tachycardia algorithms, emphasizing early identification of hemodynamic instability, streamlined drug dosing, and integration of point-of-care echocardiography in decision-making.

The central question that drives modern dysrhythmia management remains fundamentally the same question that Einthoven's work first made answerable: Is this patient's heart rate adequate to maintain perfusion, and if not, what is the fastest, safest intervention to restore hemodynamic stability? The ACLS bradycardia and tachycardia algorithms provide paramedics with a structured decision framework to answer this question rapidly, even under the immense pressure of a prehospital emergency.

SECTION 2

Core Principles & Definitions

Effective dysrhythmia management rests on a small number of foundational principles that guide every clinical decision, from the initial rhythm interpretation on the cardiac monitor to the choice between pharmacological and electrical therapy. These principles unify the bradycardia and tachycardia algorithms into a coherent clinical framework. A paramedic must internalize these concepts so deeply that they become reflexive, because the time between recognition and intervention is often measured in minutes—or less.

Heart Rate Thresholds

Bradycardia is defined as a heart rate < 60 bpm. Tachycardia is defined as a heart rate > 100 bpm. However, clinical significance depends on symptoms and hemodynamic compromise—not the number alone.

Hemodynamic Stability

The most critical assessment is whether the dysrhythmia produces signs of hemodynamic instability: hypotension (SBP < 90 mmHg), altered mental status, chest pain, or signs of shock (diaphoresis, pallor, poor perfusion). Unstable patients require immediate intervention.

Narrow vs. Wide QRS

In tachycardia, the QRS duration differentiates supraventricular (narrow, < 0.12 s) from ventricular (wide, ≥ 0.12 s) origins. This distinction fundamentally changes treatment strategy.

Regular vs. Irregular Rhythm

Rhythm regularity helps narrow the differential diagnosis. Regular narrow-complex tachycardias often respond to vagal maneuvers and adenosine. Irregular rhythms may indicate atrial fibrillation or multifocal atrial tachycardia.

Treat the Patient, Not the Monitor

A well-conditioned athlete may have a resting heart rate of 45 bpm and be completely asymptomatic. Conversely, a rate of 55 bpm in a septic patient may represent devastating cardiac compromise. Clinical context always supersedes the numeric value.

✦

KEY TAKEAWAY

Think of the heart rate like the RPM gauge on a car's tachometer. A rate that is too low (bradycardia) is like an engine idling so slowly it stalls—vital organs lose perfusion. A rate that is too high (tachycardia) is like redlining the engine—the chambers cannot fill adequately between beats, and cardiac output drops. In both cases, the fundamental problem is the same: inadequate perfusion. Your job as a paramedic is to restore the engine to its optimal operating range.

SECTION 3

Bradycardia Algorithm — Visual Overview

Figure 1. The ACLS Bradycardia Algorithm. The decision point centers on hemodynamic stability. Stable patients are monitored; unstable patients receive atropine first-line, followed by transcutaneous pacing or vasopressor infusions if atropine is ineffective.

The bradycardia algorithm begins with the recognition that a heart rate below 60 beats per minute may or may not be clinically significant. The critical branch point in the algorithm is the assessment of hemodynamic instability, which is defined by the presence of hypotension, altered mental status, signs of shock, ischemic chest discomfort, or acute heart failure. If the patient is stable, the paramedic continues to monitor and transports the patient without aggressive intervention. If the patient is unstable, the first-line pharmacological agent is atropine, administered at 1 mg intravenously, which may be repeated every 3 to 5 minutes to a maximum dose of 3 mg. Atropine works by blocking vagal (parasympathetic) tone on the sinoatrial and atrioventricular nodes. If atropine proves ineffective—particularly in cases of high-degree AV block or infranodal block—the algorithm directs the provider to transcutaneous pacing or a continuous infusion of dopamine (typically 5–20 μg/kg/min) or epinephrine (2–10 μg/min).

SECTION 4

Pharmacological & Electrical Mechanisms

Pharmacological Agents in Bradycardia

Understanding the mechanism of each intervention is essential for anticipating its effects and limitations. Atropine sulfate is a competitive antagonist at muscarinic (M₂) receptors in the heart. Because the parasympathetic vagus nerve exerts tonic inhibitory influence on the SA and AV nodes, blocking this input with atropine accelerates the firing rate of the SA node and improves AV conduction. Critically, atropine is ineffective in patients with infranodal (below the AV node) block, because the parasympathetic nervous system exerts minimal influence below the bundle of His. In these patients, transcutaneous pacing becomes the primary intervention.

CARDIAC OUTPUT

CO = HR × SV

Where CO = cardiac output (L/min), HR = heart rate (bpm), and SV = stroke volume (mL/beat). In bradycardia, the low HR directly reduces CO; in tachycardia, the shortened diastolic filling time reduces SV, paradoxically also reducing CO.

Pharmacological Agents in Tachycardia

For stable narrow-complex tachycardia, adenosine is the drug of choice. Adenosine transiently blocks conduction through the AV node by activating potassium channels and inhibiting calcium influx, effectively "resetting" re-entrant circuits that pass through the AV node (as in AVNRT and AVRT). Its half-life is less than 10 seconds, so it must be administered as a rapid IV push followed by a normal saline flush. The initial dose is 6 mg; if ineffective, 12 mg may be given and repeated once. For stable wide-complex tachycardia or polymorphic VT, amiodarone (150 mg IV over 10 minutes) is preferred, as it blocks sodium, potassium, and calcium channels while also possessing beta-blocking activity. Procainamide (20–50 mg/min IV) is an alternative for monomorphic VT in hemodynamically stable patients.

Electrical Interventions

When pharmacological measures fail or when the patient is hemodynamically unstable with tachycardia, synchronized cardioversion is the definitive intervention. Synchronization means the defibrillator senses the R wave and delivers the shock during the refractory period, avoiding the vulnerable period of the T wave that could precipitate ventricular fibrillation. Initial energy settings vary by rhythm: narrow-complex rhythms typically begin at 50–100 J (biphasic), while wide-complex rhythms begin at 100 J with escalation as needed. For unstable bradycardia, transcutaneous pacing delivers a controlled electrical impulse through pads on the chest wall to directly stimulate myocardial depolarization, with the output typically starting at 60 mA and titrated upward until electrical capture (concordance between pacer spike and QRS complex) is achieved.

DOPAMINE INFUSION RATE

Rate (mL/hr) = [Dose (μg/kg/min) × Weight (kg) × 60] ÷ Concentration (μg/mL)

For a standard dopamine drip of 400 mg in 250 mL (1,600 μg/mL), this formula allows paramedics to set the infusion pump to deliver the desired chronotropic dose (typically 5–20 μg/kg/min for bradycardia).

SECTION 5

Tachycardia Algorithm — Classification & Visual

Figure 2. The ACLS Tachycardia Algorithm (with pulse). The first decision point is hemodynamic stability. Stable patients are further classified by QRS width (narrow vs. wide) and regularity to guide pharmacological choices. Unstable patients proceed directly to synchronized cardioversion.

The tachycardia algorithm is more branched than the bradycardia algorithm because the differential diagnosis of a fast heart rate is considerably broader. The first decision remains the same—is the patient hemodynamically stable? If the answer is no, proceed immediately to synchronized cardioversion. If the patient is stable, the second question is QRS width. A narrow QRS (< 0.12 seconds) suggests a supraventricular tachycardia (SVT), which is further subdivided into regular SVT (likely AVNRT or AVRT, treated with vagal maneuvers and adenosine) or irregular SVT (likely atrial fibrillation, treated with rate control agents such as diltiazem or beta-blockers). A wide QRS (≥ 0.12 seconds) suggests possible ventricular tachycardia (VT) or SVT with aberrant conduction; regular wide-complex tachycardia is assumed to be VT until proven otherwise and is treated with amiodarone or procainamide.

⚠

Clinical Pearl

Never administer AV-nodal blocking agents (adenosine, diltiazem, beta-blockers) to a patient with a wide-complex tachycardia of uncertain origin. If the rhythm is actually VT, AV-nodal blockers can precipitate cardiovascular collapse. When in doubt, treat wide-complex tachycardia as VT.

SECTION 6

Worked Example — Prehospital Scenario

Case: 72-Year-Old Male with Symptomatic Bradycardia

1
Step 1 — Scene Assessment & Initial Findings

You respond to a 72-year-old male complaining of dizziness and near-syncope. He is pale, diaphoretic, and has a blood pressure of 78/50 mmHg. The cardiac monitor shows a regular rhythm at a rate of 38 bpm with a narrow QRS complex and no visible P waves preceding each QRS—consistent with a junctional escape rhythm.

Symptomatic bradycardia with hemodynamic instability identified.
2
Step 2 — Apply the Bradycardia Algorithm

The heart rate is < 60 bpm, and the patient has clear signs of hemodynamic instability (hypotension, altered sensorium, diaphoresis). Per the algorithm, this patient requires immediate intervention. Ensure IV/IO access is established, apply high-flow oxygen, and prepare medications.

Proceed to first-line pharmacological intervention: Atropine.
3
Step 3 — Administer Atropine

Administer atropine 1 mg IV push. After 2 minutes, the heart rate increases to 52 bpm, but blood pressure remains 82/54 mmHg and the patient is still symptomatic. Repeat atropine 1 mg IV push. After the second dose, the heart rate is 58 bpm with BP 86/58 mmHg—still inadequate.

Atropine partially effective; inadequate clinical response after 2 mg total.
4
Step 4 — Initiate Transcutaneous Pacing

Place pacing pads in anterior-posterior position. Set the pacemaker rate to 60 bpm. Begin at 60 mA output and increase until electrical capture is achieved—concordant pacer spikes followed by wide QRS complexes on the monitor. Capture is achieved at 80 mA. Increase output by 10% to 88 mA for a safety margin. Confirm mechanical capture by palpating a femoral pulse at the set rate. Administer analgesia/sedation (e.g., midazolam 2 mg IV) as the patient tolerates.

Electrical and mechanical capture confirmed at 80 mA, rate 60 bpm. BP improves to 104/68 mmHg.
5
Step 5 — Reassess & Transport

Continuously monitor the patient for loss of capture and reassess vital signs every 5 minutes. Contact the receiving facility to notify them of a patient with symptomatic bradycardia requiring transvenous pacing. Consider a dopamine infusion (5–10 μg/kg/min) as a bridge if capture is lost during transport.

Patient stabilized with transcutaneous pacing; transport to definitive care.

SECTION 7

Pharmacological Comparisons & Limitations

Drug / Intervention	Indication	Dose	Key Limitations
Atropine	Symptomatic bradycardia (1st line)	1 mg IV q3–5 min; max 3 mg	Ineffective in infranodal block (Mobitz II, 3rd-degree); avoid in transplant hearts (denervated)
Dopamine infusion	Bradycardia refractory to atropine	5–20 μg/kg/min IV	May cause tachyarrhythmias at high doses; requires infusion pump
Epinephrine infusion	Bradycardia refractory to atropine	2–10 μg/min IV	Potent vasopressor; may increase myocardial O₂ demand and ischemia
Adenosine	Stable regular narrow-complex SVT	6 mg rapid IVP → 12 mg → 12 mg	Ultra-short half-life (<10 s); must use rapid push + flush; contraindicated in wide-complex of unknown origin
Amiodarone	Stable wide-complex VT; refractory SVT	150 mg IV over 10 min; may repeat	Hypotension during infusion; long half-life (40–55 days); QT prolongation
Synchronized Cardioversion	Unstable tachycardia with pulse	Narrow: 50–100 J; Wide: 100 J; escalate	Requires sedation if conscious; may not convert atrial fibrillation; risks VF if sync fails
Transcutaneous Pacing	Unstable bradycardia refractory to atropine	Rate 60–80 bpm; output titrated to capture	Painful (requires analgesia/sedation); may not achieve capture; temporary bridge only

Comparison of key pharmacological and electrical interventions for bradycardia and tachycardia management

✦

KEY TAKEAWAY

Think of each intervention as a tool in a mechanic's toolbox. Atropine is like tapping the accelerator to wake up an idling engine—it works when the throttle cable (vagus nerve) is the problem, but it cannot fix a broken ignition system (infranodal block). Cardioversion is the equivalent of a controlled restart—resetting the engine's timing system when it is firing too fast and out of sequence. No single tool works for every problem, which is precisely why the algorithms branch into multiple pathways.

SECTION 8

Connection to Advanced Cardiac Care

While the ACLS bradycardia and tachycardia algorithms represent the standard of care for prehospital and emergency department management, they serve as the foundation for more advanced cardiac interventions encountered in critical care medicine and interventional cardiology. Understanding where these algorithms connect to advanced practice ensures that the paramedic can anticipate the trajectory of care for their patient and facilitate seamless transitions to the receiving team.

Paramedic-Level Intervention	Advanced / In-Hospital Continuation
Transcutaneous pacing for symptomatic bradycardia	Transvenous pacing — catheter-based pacing wire advanced into the right ventricle for more reliable capture and patient comfort; bridge to permanent pacemaker implantation
Adenosine for regular narrow-complex SVT	Electrophysiology (EP) study & catheter ablation — invasive mapping and destruction of accessory pathways or ectopic foci causing recurrent SVT (definitive cure)
Amiodarone for monomorphic VT	Implantable cardioverter-defibrillator (ICD) — device implantation for patients at high risk of recurrent VT/VF; provides automatic defibrillation
Synchronized cardioversion for unstable AFib/flutter	Rhythm vs. rate control strategy — long-term management decision involving anticoagulation, anti-arrhythmic drugs, or pulmonary vein isolation
Identification of Torsades de Pointes (polymorphic VT with long QT)	IV magnesium sulfate 1–2 g and overdrive pacing; genetic testing for congenital long QT syndromes; isoproterenol infusion in refractory cases

Paramedic-level interventions and their in-hospital advanced counterparts

As the scope of prehospital care continues to expand, paramedics are increasingly expected to recognize conditions like Brugada syndrome, Wolff-Parkinson-White (WPW) pattern, and acquired QT prolongation on 12-lead ECG, even if definitive management occurs in the hospital. Familiarity with these entities enhances the paramedic's ability to make informed transport decisions and provide critical information during the handoff report, ultimately improving patient outcomes.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 55-year-old long-distance runner presents with a heart rate of 48 bpm. He is alert, oriented, and denies any symptoms. His blood pressure is 128/76 mmHg. According to the ACLS bradycardia algorithm, what is the most appropriate action?

Show answer

The most appropriate action is to monitor and observe. Although this patient technically meets the definition of bradycardia (HR < 60 bpm), he demonstrates no signs of hemodynamic instability: his blood pressure is normal, he is alert and oriented, and he is asymptomatic. Well-conditioned athletes commonly have resting heart rates in the 40s due to enhanced vagal tone and increased stroke volume. The ACLS algorithm only directs intervention when bradycardia causes symptoms or hemodynamic compromise—this is the core principle of 'treat the patient, not the monitor.'

Question 2: BASIC CALCULATION

A patient with symptomatic bradycardia weighing 80 kg requires a dopamine infusion at 10 μg/kg/min. The dopamine drip is prepared as 400 mg in 250 mL of normal saline. Calculate the infusion rate in mL/hr.

Show answer

First, determine the concentration: 400 mg ÷ 250 mL = 1.6 mg/mL = 1,600 μg/mL. Then apply the formula: Rate = (Dose × Weight × 60) ÷ Concentration = (10 μg/kg/min × 80 kg × 60 min/hr) ÷ 1,600 μg/mL = 48,000 ÷ 1,600 = 30 mL/hr. This calculation is essential for setting the infusion pump correctly, and paramedics should be able to perform it rapidly. Double-checking by working backward confirms: 30 mL/hr × 1,600 μg/mL = 48,000 μg/hr ÷ 60 min = 800 μg/min ÷ 80 kg = 10 μg/kg/min.

Question 3: INTERMEDIATE

You are managing a 64-year-old female with a regular narrow-complex tachycardia at 180 bpm. She is alert but complains of palpitations and mild lightheadedness. BP is 102/68 mmHg. You administer adenosine 6 mg rapid IVP with no effect. What is your next step, and why might the first dose have been ineffective?

Show answer

The next step is to administer adenosine 12 mg rapid IVP. The initial 6 mg dose may have been ineffective for several reasons: the dose may not have been pushed rapidly enough (adenosine has a half-life of < 10 seconds and must reach the heart before it is metabolized), the IV site may have been too distal (a proximal antecubital or external jugular site is preferred), or the saline flush may not have been given immediately after the push. Additionally, patients on caffeine or theophylline may require higher doses because these methylxanthines are competitive adenosine receptor antagonists. If the 12 mg dose is also ineffective, it may be repeated once. If the rhythm still does not convert, consider alternative diagnoses (atrial flutter, atrial tachycardia) and consult medical direction regarding calcium channel blockers or beta-blockers.

Question 4: APPLIED

You respond to a 58-year-old male with a wide-complex tachycardia at 160 bpm. He is confused, diaphoretic, with a BP of 72/40 mmHg. His wife reports he has a history of a previous myocardial infarction. Walk through your management from the moment you identify the rhythm.

Show answer

This patient presents with a wide-complex tachycardia with hemodynamic instability (hypotension, altered mental status). Given the history of prior MI, this rhythm is most likely monomorphic ventricular tachycardia originating from scar tissue in the damaged myocardium. Per the ACLS tachycardia algorithm, unstable tachycardia with a pulse requires immediate synchronized cardioversion. Apply pads, ensure sync mode is activated (confirm sync markers on the R waves), and deliver an initial shock at 100 J (biphasic). If the patient has any level of consciousness, administer sedation (midazolam 2–5 mg IV or ketamine 1–2 mg/kg IV) if time and hemodynamic status permit—but do not delay cardioversion for sedation if the patient is deteriorating. After successful cardioversion, obtain a 12-lead ECG, start an amiodarone maintenance infusion (1 mg/min for 6 hours), and transport with continuous monitoring. If the rhythm recurs or the patient deteriorates into pulseless VT or VF, switch to unsynchronized defibrillation at maximum energy and initiate the cardiac arrest algorithm.

Question 5: CRITICAL THINKING

A 28-year-old male presents with an irregular wide-complex tachycardia at 200 bpm. His 12-lead ECG shows a short PR interval and a delta wave during the brief periods of sinus rhythm between the tachycardic runs. A well-meaning EMT partner begins to administer adenosine. Why is this potentially lethal, what is the likely underlying condition, and what should be done instead?

Show answer

The short PR interval and delta wave are hallmarks of Wolff-Parkinson-White (WPW) syndrome, in which an accessory pathway (bundle of Kent) allows impulses to bypass the AV node. The irregular wide-complex tachycardia in this context is most likely atrial fibrillation with pre-excitation. Administering adenosine, diltiazem, or any AV-nodal blocking agent is potentially lethal because blocking the AV node removes the only rate-limiting checkpoint—all fibrillatory impulses then conduct exclusively through the accessory pathway, which can conduct at extremely rapid rates, precipitating ventricular fibrillation and cardiac arrest. The correct management depends on stability. If unstable, perform immediate synchronized cardioversion. If stable, the appropriate pharmacological agent is procainamide (which slows conduction through the accessory pathway) or ibutilide, and urgent consultation with medical direction or cardiology is warranted. This case illustrates why accurate 12-lead ECG interpretation is a critical paramedic skill: a seemingly routine tachycardia can become fatal if the wrong drug is administered.

SUMMARY

Lesson Summary

Summary

Management of bradycardia and tachycardia follows structured ACLS algorithms built around one pivotal question: is the patient hemodynamically stable? For bradycardia (HR < 60 bpm), atropine 1 mg IV is first-line therapy for unstable patients, followed by transcutaneous pacing or vasopressor infusions (dopamine or epinephrine) when atropine is ineffective. Remember that atropine is unlikely to work for infranodal blocks (Mobitz type II, third-degree AV block).

For tachycardia (HR > 100 bpm with a pulse), unstable patients receive immediate synchronized cardioversion. Stable patients are classified by QRS width (narrow vs. wide) and regularity. Regular narrow-complex SVT is treated with vagal maneuvers and adenosine; wide-complex tachycardia of uncertain origin is treated as VT with amiodarone or procainamide. The overarching principle remains constant: treat the patient, not the monitor—clinical context and hemodynamic status always guide decision-making over numeric thresholds alone.